Metal-Based Nanoparticles for Cardiovascular Diseases

Int J Mol Sci. 2024 Jan 13;25(2):1001. doi: 10.3390/ijms25021001.

Abstract

Globally, cardiovascular diseases (CVDs) are the leading cause of death and disability. While there are many therapeutic alternatives available for the management of CVDs, the majority of classic therapeutic strategies were found to be ineffective at stopping or significantly/additionally slowing the progression of these diseases, or they had unfavorable side effects. Numerous metal-based nanoparticles (NPs) have been created to overcome these limitations, demonstrating encouraging possibilities in the treatment of CVDs due to advancements in nanotechnology. Metallic nanomaterials, including gold, silver, and iron, come in various shapes, sizes, and geometries. Metallic NPs are generally smaller and have more specialized physical, chemical, and biological properties. Metal-based NPs may come in various forms, such as nanoshells, nanorods, and nanospheres, and they have been studied the most. Massive potential applications for these metal nanomaterial structures include supporting molecular imaging, serving as drug delivery systems, enhancing radiation-based anticancer therapy, supplying photothermal transforming effects for thermal therapy, and being compounds with bactericidal, fungicidal, and antiviral qualities that may be helpful for cardiovascular diseases. In this context, the present paper aims to review the applications of relevant metal and metal oxide nanoparticles in CVDs, creating an up-to-date framework that aids researchers in developing more efficient treatment strategies.

Keywords: cardiovascular diseases; cerium oxide nanoparticles; gold nanoparticles; iron oxide nanoparticles; metal-based nanoparticles; nanomedicine; silver nanoparticles.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents
  • Cardiovascular Diseases* / drug therapy
  • Data Accuracy
  • Humans
  • Metal Nanoparticles* / therapeutic use
  • Nanoshells*

Substances

  • Anti-Bacterial Agents

Grants and funding

The research leading to these results has received funding from the EEA Grants 2014-2021, under Project contract no. 33/2021.